Alector (NASDAQ:ALEC) is a biopharmaceutical entity focused on developing therapies that harness the immune system to tackle neurodegenerative diseases and cancer. At the core of its operations, Alector employs a robust technology platform aimed at identifying and therapeutically targeting immune dysregulation within the human body. Its projects are primarily aligned towards advancing a diverse portfolio of antibody-based treatments that promise innovative solutions for patients grappling with complex disorders such as Alzheimer's disease, frontotemporal dementia, and other severe neurological conditions. Objectives of Alector are deeply rooted in the ambition to bring groundbreaking treatments from the lab to the clinic, aiming to fundamentally change how debilitating diseases are fought, offering new hope and improved quality of life for those affected.